auremolimab
Pre-clinical- Indications
- Vitiligo, Autoimmune diseases, Inflammatory diseases
Company intelligence / Profile preview
Villaris Therapeutics
Cary, North Carolina, United Statesvillaristherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Villaris developed auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody designed to target and deplete autoreactive resident memory T cells (TRM). Pre-clinical data demonstrated high potency, selectivity, and efficacy in vitiligo models. IND-enabling studies were underway at the time of acquisition, with clinical development expected to begin in 2023.
- Therapeutic areas
- ImmunologyDermatology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Medicxi Ventures (investment partner)
Beyond the preview
Go deeper on Villaris Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Villaris Therapeutics.